A Phase 1 interventional study of Apixaban and Apixaban in End Stage Renal Disease, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-11.
Sponsored by Bristol-Myers Squibb · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 97 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 477th largest by enrollment of the 638 interventional ones that give a count, is one of 32 that started in 2011, is one of 89 in phase 1, and was the 249th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:
United Therapeutics · Sites in United States
Ages 40–70
Xeno Holdings (US), LLC dba ChoironeX · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 18+
Basilea Pharmaceutica · Sites in United States
Ages 18–80 · Healthy volunteers
University of Washington · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
765 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 119 · Phase 2 130 · Phase 3 89 · Phase 4 61
First in 1995; this study’s year is marked. 32 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 48 across the 638 interventional studies, 100 across the 121 observational. Of the 610 that completed or were terminated, 267 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
275 of 765 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 7 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
43 of the studies in Kidney Failure, Chronic with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT05931276Phase 3VA Office of Research and DevelopmentCSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes | 2026-12-31 |
| NCT03321656Phase 3Roberto GedalyImpact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile | 2027-03-31 |
| NCT05908084Phase 3Humacyte, Inc.To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | 2027-06 |
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
Add all 43 to your calendar (.ics) → With an account.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the pharmacokinetics of a single oral dose of 5 mg Apixaban in subjects with normal renal function and subjects with end stage renal disease (ESRD) maintained with hemodialysis.
Primary Purpose : To provide a clear understanding of the pharmacokinetics of Apixaban in subjects with ESRD and to determine the effect of hemodialysis on Apixaban pharmacokinetics .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Apixaban
Drug: Apixaban
Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Single 5mg Oral Dose of Apixaban
Maximum observed plasma concentration (Cmax) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanograms per milliliter (ng/mL).
Time frame: 24 hours pre-dose to 72 hours post-dose
Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Metabolite BMS-730823
Maximum observed plasma concentration (Cmax) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanograms per milliliter (ng/mL).
Time frame: From 24 hours pre-dose to 72 hours post-dose
Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Single 5mg Oral Dose of Apixaban
Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanogram hours per milliliter (ng\*h/mL).
Time frame: 24 hours pre-dose to 72 hours post-dose
Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Metabolite BMS-730823
Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanogram hours per milliliter (ng\*h/mL).
Time frame: From 24 hours pre-dose to 72 hours post-dose
Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Single 5mg Oral Dose of Apixaban
The area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanogram hours per milliliter (ng\*h/mL).
Time frame: From 24 hours pre-dose to 72 hours post-dose
Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-730823
The area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanogram hours per milliliter (ng\*h/mL).
Time frame: 24 hours pre-dose to 72 hours post-dose
Mean Plasma Terminal Half-life (T-Half) of Single 5mg Oral Dose of Apixaban
Plasma terminal half-life (T-Half) for apixaban was derived from plasma concentrations versus time data. Means were reported in hours.
Time frame: From 24 hours pre-dose to 72 hours post-dose
Mean Plasma Terminal Half-life (T-Half) of BMS-730823
Mean plasma terminal half-life (T-Half) for BMS-730823 was derived from plasma concentrations versus time data.
Time frame: 24 hours pre-dose to 72 hours post-dose
Median Time of Maximum Observed Plasma Concentration (Tmax) of a Single 5 mg Oral Dose of Apixaban
Time of maximum observed plasma concentration (Tmax) for apixaban was derived from plasma concentrations versus time data. Medians were reported in hours.
Time frame: From 24 hours pre-dose to 72 hours post-dose
Median Time of Maximum Observed Plasma Concentration (Tmax) of Metabolite BMS-730823
Time of maximum observed plasma concentration (Tmax) for BMS-730823 was derived from plasma concentrations versus time data. Medians were reported in hours.
Time frame: From 24 hours pre-dose to 72 hours post-dose
Geometric Mean of Area Under the Plasma Concentration-Time Curve From 2 to 6 Hours (AUC(2-6)) for Apixaban
Area under the plasma concentration-time curve from 2 hours to 6 hours (AUC(2-6) for Apixaban was measured in participants with ESRD during dialysis in Period 1 only. Geometric Means were reported in nanogram hours per milliliter (ng\*hr/mL) and were determined from blood samples both entering and exiting the dialyzer.
Time frame: 2 to 6 hours post-dose
Geometric Mean of Area Under the Plasma Concentration-Time Curve From 2 to 6 Hours (AUC(2-6)) for BMS-730823
Area under the plasma concentration-time curve from 2 hours to 6 hours (AUC(2-6) for BMS-730823 was measured in participants with ESRD during dialysis in Period 1 only. Geometric Means were reported in nanogram hours per milliliter (ng\*hr/mL) and were determined from blood samples both entering and exiting the dialyzer.
Time frame: 2 to 6 hours post-dose
Mean Percent Dose of Apixaban Recovered in Urine (%UR)
The percent dose recovered in urine was calculated by dividing the cumulative amount of unchanged apixaban excreted in urine from the time of dose up to 72 hours post-dose by the apixaban dose administered.
Time frame: 24 hours pre-dose to 72 hours post-dose
Mean Percent Dose of Apixaban Recovered in Dialysate (%DR)
Percent dose of Apixaban recovered in dialysate (%DR) was calculated by dividing the cumulative amount of apixaban excreted in each dialysate collection over 2-6 hours (DR(2-6)) by the apixaban dose. %DR was recorded only in period 1.
Time frame: 2 to 6 hours post-dose
Mean Renal Clearance (CLR) of Apixaban
Renal clearance (CLR) was calculated by dividing the cumulative amount of apixaban excreted in urine by the respective cumulative plasma AUC over the same urine collection interval. Geometric means were reported in milliliters per minute (mL/min).
Time frame: 24 hours pre-dose to 72 hours post-dose
Mean Renal Clearance (CLR) of BMS-730823
Renal clearance (CLR) was calculated by dividing the cumulative amount of BMS-730823 excreted in urine by the respective cumulative plasma AUC over the same urine collection interval. Geometric means were reported in milliliters per minute (mL/min).
Time frame: 24 hours pre-dose to 72 hours post-dose
Mean Hemodialysis Clearance (CLD) of Apixaban
Hemodialysis clearance (CLD) was calculated by dividing the cumulative amount of apixaban excreted in dialysate by the respective cumulative plasma AUC over the same dialysate collection interval (AUC(2-6) entering). CLD measurements occurred only in period 1. Geometric means were reported in milliliters per minute (mL/min).
Time frame: 2 to 6 hours post-dose
Mean Hemodialysis Clearance (CLD) of BMS-730823
Hemodialysis clearance (CLD) was calculated by dividing the cumulative amount of BMS-730823 excreted in dialysate by the respective cumulative plasma AUC over the same dialysate collection interval (AUC(2-6) entering). CLD measurements occurred only in period 1. Geometric means were reported in milliliters per minute (mL/min).
Time frame: 2 to 6 hours post-dose
Percentage of Apixaban Extracted During Hemodialysis
The percentage of apixaban extracted during hemodialysis (extraction ratio) was calculated using the formula \[plasma AUC(2-6) exiting - AUC(2-6) entering\] / \[AUC(2-6) entering\] and converted to a percentage. The extraction ratio was measured in period 1 only, and was reported as a percentage.
Time frame: 2 to 6 hours post-dose
Percentage of BMS-730823 Extracted During Hemodialysis
The percentage of BMS-730823 extracted during hemodialysis (extraction ratio) was calculated using the formula \[plasma AUC(2-6)exiting - AUC(2-6)entering\] / \[AUC(2-6) entering\] and converted to a percentage. The extraction ratio was measured in period 1 only, and was reported as a percentage.
Time frame: 2 to 6 hours post-dose
Mean Maximum Percent Change From Baseline International Normalized Ratio (INR) Following a Single 5 mg Oral Dose of Apixaban
The mean maximum percent change in baseline for INR was reported for each arm. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.
Time frame: From 24 hours pre-dose to 72 hours post-dose
Mean Maximum Percent Change From Baseline Prothrombin Time (PT) Following a Single 5 mg Oral Dose of Apixaban
The mean maximum percent change in Prothrombin Time (PT) from baseline was reported for all treated participants. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.
Time frame: From 24 hours pre-dose to 72 hours post-dose
Mean Maximum Percent Change From Baseline Activated Partial Thromboplastin Time (aPTT) Following a Single Oral Dose of 5 mg Apixaban
The mean maximum percent change in Activated Partial Thromboplastin Time (aPTT) from baseline was reported for all treated participants. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.
Time frame: From 24 hours pre-dose to 72 hours post-dose
Mean Peak Anti-FXa Activity Following a Single Oral Dose of 5 mg Apixaban
Anti-FXa activity was assessed from an activity-time profile for doses both before and after hemodialysis. Maximal means were reported in International Units per milliliter (IU/mL).
Time frame: From 24 hours pre-dose to 72 hours post-dose
Number of Participants With Laboratory Marked Abnormalities
ULN=Upper Limit of Normal, LLN=Lower Limit of Normal, Pre-Rx= Baseline value. BUN=Blood Urea Nitrogen (mmol/L=millimoles per Liter): High if BUN \> 1.1\*ULN (if Pre-Rx\>ULN: \>1.25\*Pre-Rx). Platelet count (\*10\^9 cell/L): Low if Platelet Count \< 0.85\*LLN (if Pre-Rx\<LLN: \<0.85\*Pre-Rx). Creatine (umol/L=micromoles per Liter): High if Creatine \> 1.5\*ULN (if Pre-Rx\>ULN: \>1.33\*Pre-Rx). Calcium, Total (mmol/L): High if Calcium \> 1.5\*ULN (if Pre-Rx\>ULN: \>1.33\*Pre-Rx). Potassium, serum (mmol/L): High if Potassium \> 1.1\*ULN (if Pre-Rx\>ULN: \>1.1\*Pre-Rx; if Pre-Rx\<LLN: \>ULN). Phosphorus, Inorganic (mmol/L): Low if Phosphate \< 0.85\*LLN (if Pre-Rx\>ULN: \<LLN). Lactate dehydrogenase (U/L=Units per Liter): High if Lactate Dehydrogenase \> 1.25\*ULN (if Pre-Rx\>ULN: \>1.5\*Pre-Rx).
Time frame: From 24 hours pre-dose to 72 hours post-dose
Number of Participants Who Died or Experienced Serious Adverse Events (SAEs) or Adverse Events Leading to Discontinuation
The number of participants who died or experienced SAEs or AEs leading to discontinuation was reported for each arm. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4= Potentially Life-threatening or disabling.
Time frame: From Day 1 to 30 days post study discontinuation
| Milestone | Normal Renal Function | ESRD Maintained With Hemodialysis |
|---|---|---|
| Started | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
Maximum observed plasma concentration (Cmax) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanograms per milliliter (ng/mL).
| ng/mL | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Single 5mg Oral Dose of Apixaban | 125.6 ± 29 | 98.9 ± 29 | 113.6 ± 31 |
Maximum observed plasma concentration (Cmax) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanograms per milliliter (ng/mL).
| ng/mL | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Metabolite BMS-730823 | 10.8 ± 38 | 15.9 ± 48 | 20.0 ± 39 |
Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanogram hours per milliliter (ng\*h/mL).
| ng*hr/mL | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Single 5mg Oral Dose of Apixaban | 1205 ± 29 | 1430 ± 41 | 1673 ± 24 |
Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanogram hours per milliliter (ng\*h/mL).
| ng*hr/mL | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Metabolite BMS-730823 | 205 ± 69 | 746 ± 56 | 953 ± 33 |
The area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanogram hours per milliliter (ng\*h/mL).
| ng*hr/mL | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Single 5mg Oral Dose of Apixaban | 1265 ± 30 | 1474 ± 44 | 1717 ± 24 |
The area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanogram hours per milliliter (ng\*h/mL).
| ng*h/mL | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-730823 | NA ± NA | NA ± NA | NA ± NA |
Plasma terminal half-life (T-Half) for apixaban was derived from plasma concentrations versus time data. Means were reported in hours.
| hours | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| Mean Plasma Terminal Half-life (T-Half) of Single 5mg Oral Dose of Apixaban | 20.0 ± 14.45 | 12.5 ± 3.14 | 12.7 ± 3.40 |
Mean plasma terminal half-life (T-Half) for BMS-730823 was derived from plasma concentrations versus time data.
| hours | ESRD Maintained With Hemodialysis |
|---|---|
| Mean Plasma Terminal Half-life (T-Half) of BMS-730823 | NA ± NA |
Time of maximum observed plasma concentration (Tmax) for apixaban was derived from plasma concentrations versus time data. Medians were reported in hours.
| hours | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| Median Time of Maximum Observed Plasma Concentration (Tmax) of a Single 5 mg Oral Dose of Apixaban | 2.00 (1.0 to 4.0) | 2.00 (1.0 to 6.0) | 2.00 (2.0 to 6.0) |
Time of maximum observed plasma concentration (Tmax) for BMS-730823 was derived from plasma concentrations versus time data. Medians were reported in hours.
| hours | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| Median Time of Maximum Observed Plasma Concentration (Tmax) of Metabolite BMS-730823 | 9.00 (6.0 to 12.0) | 15.00 (8.0 to 60.0) | 21.00 (12.0 to 36.0) |
Area under the plasma concentration-time curve from 2 hours to 6 hours (AUC(2-6) for Apixaban was measured in participants with ESRD during dialysis in Period 1 only. Geometric Means were reported in nanogram hours per milliliter (ng\*hr/mL) and were determined from blood samples both entering and exiting the dialyzer.
| ng*hr/mL | ESRD Maintained With Hemodialysis |
|---|---|
| Blood entering dialyzer | 309 ± 29 |
| Blood exiting dialyzer | 312 ± 28 |
Area under the plasma concentration-time curve from 2 hours to 6 hours (AUC(2-6) for BMS-730823 was measured in participants with ESRD during dialysis in Period 1 only. Geometric Means were reported in nanogram hours per milliliter (ng\*hr/mL) and were determined from blood samples both entering and exiting the dialyzer.
| ng*hr/mL | ESRD Maintained With Hemodialysis |
|---|---|
| Blood entering dialyzer | 15.0 ± 102 |
| Blood exiting dialyzer | 17.7 ± 96 |
The percent dose recovered in urine was calculated by dividing the cumulative amount of unchanged apixaban excreted in urine from the time of dose up to 72 hours post-dose by the apixaban dose administered.
| percent of dose recovered in urine | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| Mean Percent Dose of Apixaban Recovered in Urine (%UR) | 18.397 ± 8.5545 | 0.145 ± 0.0881 | 0.181 ± 0.1391 |
Percent dose of Apixaban recovered in dialysate (%DR) was calculated by dividing the cumulative amount of apixaban excreted in each dialysate collection over 2-6 hours (DR(2-6)) by the apixaban dose. %DR was recorded only in period 1.
| percent of dose recovered in dialysate | ESRD Maintained With Hemodialysis |
|---|---|
| Mean Percent Dose of Apixaban Recovered in Dialysate (%DR) | 6.68 ± 1.408 |
Renal clearance (CLR) was calculated by dividing the cumulative amount of apixaban excreted in urine by the respective cumulative plasma AUC over the same urine collection interval. Geometric means were reported in milliliters per minute (mL/min).
| mL/min | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| Mean Renal Clearance (CLR) of Apixaban | 11.263 ± 44 | 0.020 ± 70 | 0.020 ± 80 |
Renal clearance (CLR) was calculated by dividing the cumulative amount of BMS-730823 excreted in urine by the respective cumulative plasma AUC over the same urine collection interval. Geometric means were reported in milliliters per minute (mL/min).
| mL/min | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| Mean Renal Clearance (CLR) of BMS-730823 | 6.36 ± 62 | NA ± NA | NA ± NA |
Hemodialysis clearance (CLD) was calculated by dividing the cumulative amount of apixaban excreted in dialysate by the respective cumulative plasma AUC over the same dialysate collection interval (AUC(2-6) entering). CLD measurements occurred only in period 1. Geometric means were reported in milliliters per minute (mL/min).
| mL/min | ESRD Maintained With Hemodialysis |
|---|---|
| Mean Hemodialysis Clearance (CLD) of Apixaban | 17.7 ± 19 |
Hemodialysis clearance (CLD) was calculated by dividing the cumulative amount of BMS-730823 excreted in dialysate by the respective cumulative plasma AUC over the same dialysate collection interval (AUC(2-6) entering). CLD measurements occurred only in period 1. Geometric means were reported in milliliters per minute (mL/min).
| mL/min | ESRD Maintained With Hemodialysis |
|---|---|
| Mean Hemodialysis Clearance (CLD) of BMS-730823 | NA ± NA |
The percentage of apixaban extracted during hemodialysis (extraction ratio) was calculated using the formula \[plasma AUC(2-6) exiting - AUC(2-6) entering\] / \[AUC(2-6) entering\] and converted to a percentage. The extraction ratio was measured in period 1 only, and was reported as a percentage.
| percentage of apixaban extracted | ESRD Maintained With Hemodialysis |
|---|---|
| Percentage of Apixaban Extracted During Hemodialysis | -1.1 ± 5.65 |
The percentage of BMS-730823 extracted during hemodialysis (extraction ratio) was calculated using the formula \[plasma AUC(2-6)exiting - AUC(2-6)entering\] / \[AUC(2-6) entering\] and converted to a percentage. The extraction ratio was measured in period 1 only, and was reported as a percentage.
| percentage of BMS-730823 extracted | ESRD Maintained With Hemodialysis |
|---|---|
| Percentage of BMS-730823 Extracted During Hemodialysis | -19.9 ± 25.32 |
The mean maximum percent change in baseline for INR was reported for each arm. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.
| maximum percent change from baseline | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| Mean Maximum Percent Change From Baseline International Normalized Ratio (INR) Following a Single 5 mg Oral Dose of Apixaban | 31.5 ± 56.59 | 16.6 ± 10.60 | 16.8 ± 7.15 |
The mean maximum percent change in Prothrombin Time (PT) from baseline was reported for all treated participants. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.
| maximum percent change from baseline | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| Mean Maximum Percent Change From Baseline Prothrombin Time (PT) Following a Single 5 mg Oral Dose of Apixaban | 32.4 ± 58.31 | 16.9 ± 10.98 | 17.4 ± 7.28 |
The mean maximum percent change in Activated Partial Thromboplastin Time (aPTT) from baseline was reported for all treated participants. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.
| maximum percent change from baseline | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| Mean Maximum Percent Change From Baseline Activated Partial Thromboplastin Time (aPTT) Following a Single Oral Dose of 5 mg Apixaban | 19.9 ± 20.40 | 7.0 ± 9.62 | 23.0 ± 14.81 |
Anti-FXa activity was assessed from an activity-time profile for doses both before and after hemodialysis. Maximal means were reported in International Units per milliliter (IU/mL).
| IU/mL | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| Mean Peak Anti-FXa Activity Following a Single Oral Dose of 5 mg Apixaban | 1.47 ± 0.659 | 1.03 ± 0.491 | 1.29 ± 0.579 |
ULN=Upper Limit of Normal, LLN=Lower Limit of Normal, Pre-Rx= Baseline value. BUN=Blood Urea Nitrogen (mmol/L=millimoles per Liter): High if BUN \> 1.1\*ULN (if Pre-Rx\>ULN: \>1.25\*Pre-Rx). Platelet count (\*10\^9 cell/L): Low if Platelet Count \< 0.85\*LLN (if Pre-Rx\<LLN: \<0.85\*Pre-Rx). Creatine (umol/L=micromoles per Liter): High if Creatine \> 1.5\*ULN (if Pre-Rx\>ULN: \>1.33\*Pre-Rx). Calcium, Total (mmol/L): High if Calcium \> 1.5\*ULN (if Pre-Rx\>ULN: \>1.33\*Pre-Rx). Potassium, serum (mmol/L): High if Potassium \> 1.1\*ULN (if Pre-Rx\>ULN: \>1.1\*Pre-Rx; if Pre-Rx\<LLN: \>ULN). Phosphorus, Inorganic (mmol/L): Low if Phosphate \< 0.85\*LLN (if Pre-Rx\>ULN: \<LLN). Lactate dehydrogenase (U/L=Units per Liter): High if Lactate Dehydrogenase \> 1.25\*ULN (if Pre-Rx\>ULN: \>1.5\*Pre-Rx).
| participants | Normal Renal Function | ESRD Maintained With Hemodialysis |
|---|---|---|
| BUN | 0 | 4 |
| Platelet count | 0 | 1 |
| Creatine | 0 | 1 |
| Potassium | 0 | 1 |
| Phosphorus | 0 | 1 |
| Lactate dehydrogenase | 0 | 1 |
The number of participants who died or experienced SAEs or AEs leading to discontinuation was reported for each arm. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4= Potentially Life-threatening or disabling.
| participants | Normal Renal Function | ESRD Maintained With Hemodialysis |
|---|---|---|
| Deaths | 0 | 0 |
| SAEs | 0 | 0 |
| AEs leading to discontinuation | 0 | 0 |
Collected over From Day 1 until 30 days post discontinuation, up to September 2011 (approximately 3 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Normal Renal Function | — | 0/8 (0%) | 0/8 (0%) |
| ESRD Dose Before Hemodialysis | — | 0/8 (0%) | 2/8 (25%) |
| ESRD Dose After Hemodialysis | — | 0/8 (0%) | 1/8 (12.5%) |
| Event | Normal Renal Function | ESRD Dose Before Hemodialysis | ESRD Dose After Hemodialysis |
|---|---|---|---|
| HeadacheNervous system disorders | 0/8 | 1/8 | 1/8 |
| ConstipationGastrointestinal disorders | 0/8 | 1/8 | 0/8 |
| Influenza like illnessGeneral disorders | 0/8 | 1/8 | 0/8 |
| SomnolenceNervous system disorders | 0/8 | 1/8 | 0/8 |
| Procedural hypotensionInjury, poisoning and procedural complications | 0/8 | 1/8 | 0/8 |
All treated participants
| Age, Continuous(years) | Normal Renal Function | ESRD Maintained With Hemodialysis | Total |
|---|---|---|---|
| Mean | 47.0 ± 7.7 | 46.9 ± 7.9 | 46.9 ± 7.5 |
| Sex: Female, Male(Participants) | Normal Renal Function | ESRD Maintained With Hemodialysis | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 6 | 6 | 12 |
The record gives a start of Jun 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 5 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban